Impressions of the Annual General Meeting 2023
Gilbert Achermann led Ypsomed's General Meeting for the first time as Chairman of the Board of Directors on 28 June, welcoming more than 360 shareholders to the Burgdorf Market Hall. In addition to introducing new members to the management team, CEO Simon Michel presented the positive business results and explained why the share price performance has more than doubled in recent years.
"Ypsomed is in a state of transition," explained Simon Michel at the presentation of the annual figures. That this can definitely be interpreted positively is shown by over half a billion in sales - a record result. Despite the sale of DiaExpert, Ypsomed achieved growth of 20%. Four global trends play into our hands: people with chronic conditions can self-administer medications at home and do not always have to go to the hospital for an appointment. In addition, new drugs nowadays and in the future will increasingly have to be injected. Thanks to biosimilars, medicines are no longer available only in Western countries, but also in India or China, for example. Last but not least, digitalization is opening up new areas of business for us.
Many thanks to the numerous shareholders who made the journey to the Markthalle to actively exercise their voting rights. We hope that we were able to present to them the good development of Ypsomed as well as a joyful outlook for the future. In addition, we are pleased to welcome new faces to the management team. With Sébastien Delarive and Nicolas Meyer, we are ideally positioned for the tasks ahead,
says Simon Michel about the General Meeting.
The next Annual General Meeting will be held on June 26, 2024.
